Form 4: GeneDx CFO Kevin Feeley Executes Options and Sells Shares Under Pre-Arranged Trading Plan

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, exercised stock options and subsequently sold a portion of his Class A Common Stock shares on July 9, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• On July 9, 2025, Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp., exercised employee stock options to acquire 1,245 shares of Class A Common Stock at an exercise price of $32.67 per share.
• Concurrently, Mr. Feeley sold 5,278 shares of Class A Common Stock at a price of $93 per share.
• This sale was executed under a Rule 10b5-1 trading plan, which was adopted on August 21, 2024.
• Following these transactions, Mr. Feeley directly beneficially owns 3,392 shares of Class A Common Stock and options to purchase an additional 6,228 shares of Class A Common Stock.
• Additionally, Mr. Feeley holds restricted stock units (RSUs) representing contingent rights to receive up to 135,762 shares and other options to purchase up to 20,924 shares, which vest according to their respective terms.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's insider selling, it's part of a pre-planned 10b5-1 program, which mitigates negative interpretations. The executive also retains significant equity holdings (shares, RSUs, and options), indicating continued alignment with shareholder interests.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new negative information.
• The CFO continues to hold a significant number of shares, RSUs, and options, aligning his interests with shareholders.
• The exercise price of the options ($32.67) is significantly lower than the sale price ($93), indicating a profitable transaction for the insider.

Negatives

• A net disposition of shares by a key executive, even if planned, can sometimes be perceived negatively by the market.
• The number of shares sold (5,278) is greater than the number of shares acquired through option exercise (1,245), resulting in a net decrease in direct share ownership.

Future Outlook

NA

Industry Context

This transaction is a routine insider equity compensation event common across all industries for publicly traded companies. It does not directly relate to broader industry trends in the biotechnology or healthcare sector beyond the general practice of executive compensation.

Stakeholder Impact

• Shareholders: The transaction represents a routine insider sale under a pre-planned program, which may have a minor, temporary impact on market sentiment. The executive's continued significant equity holdings suggest ongoing alignment of interests.
• Employees: The transaction is specific to a senior executive's compensation and does not directly impact the broader employee base beyond general company performance implications.

Key Dates

Recommendation

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Kevin Feeley, Chief Financial Officer, Rule 10b5-1 Plan, Equity Compensation, Restricted Stock Units